AEON Biopharma Appoints Rob Bancroft as CEO

Dow Jones

04-22

By Katherine Hamilton

AEON Biopharma named Rob Bancroft as its new chief executive.

The Irvine, Calif. biopharmaceutical company, which is working on developing an alternative to Botox, said Monday Bancroft brings experience in the therapeutic toxin industry with 25 years of leadership under his belt.

Bancroft is set to step into the role on April 29. He previously worked as general manager of the therapeutics business at Revance Therapeutics.

Bancroft succeeds Marc Forth, who stepped down on April 4 to pursue another opportunity.

Forth received total compensation of about $4 million as chief executive in 2023, according to a separate filing with the Securities and Exchange Commission.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

April 21, 2025 16:25 ET (20:25 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2529588453"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2529588453\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2529588453?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-22 04:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2529588453","market":"sh","top_or_hot":-1,"title":"AEON Biopharma Appoints Rob Bancroft as CEO","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/AEON\">AEON Biopharma</a> named Rob Bancroft as its new chief executive. \n</p>\n<p>\n  The Irvine, Calif. biopharmaceutical company, which is working on developing an alternative to Botox, said Monday Bancroft brings experience in the therapeutic toxin industry with 25 years of leadership under his belt. \n</p>\n<p>\n  Bancroft is set to step into the role on April 29. He previously worked as general manager of the therapeutics business at Revance <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>. \n</p>\n<p>\n  Bancroft succeeds Marc Forth, who stepped down on April 4 to pursue another opportunity. \n</p>\n<p>\n  Forth received total compensation of about $4 million as chief executive in 2023, according to a separate filing with the Securities and Exchange Commission. \n</p>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 21, 2025 16:25 ET (20:25 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AEON Biopharma Appoints Rob Bancroft as CEO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAEON Biopharma Appoints Rob Bancroft as CEO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-04-22 04:25</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/AEON\">AEON Biopharma</a> named Rob Bancroft as its new chief executive. \n</p>\n<p>\n  The Irvine, Calif. biopharmaceutical company, which is working on developing an alternative to Botox, said Monday Bancroft brings experience in the therapeutic toxin industry with 25 years of leadership under his belt. \n</p>\n<p>\n  Bancroft is set to step into the role on April 29. He previously worked as general manager of the therapeutics business at Revance <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>. \n</p>\n<p>\n  Bancroft succeeds Marc Forth, who stepped down on April 4 to pursue another opportunity. \n</p>\n<p>\n  Forth received total compensation of about $4 million as chief executive in 2023, according to a separate filing with the Securities and Exchange Commission. \n</p>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 21, 2025 16:25 ET (20:25 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AEON","symbol_name":"AEON Biopharma","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2529588453","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2529588453","pubTimestamp":1745267100,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"AEON Biopharma named Rob Bancroft as its new chief executive.The Irvine, Calif. biopharmaceutical company, which is working on developing an alternative to Botox, said Monday Bancroft brings experience in the therapeutic toxin industry with 25 years of leadership under his belt.Bancroft is set to step into the role on April 29. He previously worked as general manager of the therapeutics business at Revance Therapeutics.Bancroft succeeds Marc Forth, who stepped down on April 4 to pursue another opportunity.Forth received total compensation of about $4 million as chief executive in 2023, according to a separate filing with the Securities and Exchange Commission.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AEON":"AEON Biopharma"},"translate_title":"AEON Biopharma任命Rob Bancroft为首席执行官","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AEON":1},"content_text":"By Katherine Hamilton \n\n\nAEON Biopharma named Rob Bancroft as its new chief executive. \n\n\n  The Irvine, Calif. biopharmaceutical company, which is working on developing an alternative to Botox, said Monday Bancroft brings experience in the therapeutic toxin industry with 25 years of leadership under his belt. \n\n\n  Bancroft is set to step into the role on April 29. He previously worked as general manager of the therapeutics business at Revance Therapeutics. \n\n\n  Bancroft succeeds Marc Forth, who stepped down on April 4 to pursue another opportunity. \n\n\n  Forth received total compensation of about $4 million as chief executive in 2023, according to a separate filing with the Securities and Exchange Commission. \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n  (END) Dow Jones Newswires\n\n\n  April 21, 2025 16:25 ET (20:25 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}